Company Update (NASDAQ:AMGN): Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

[PR Newswire] – THOUSAND OAKS, Calif. and LONDON, Dec. 11, 2014 /PRNewswire/ — Amgen (AMGN) and AstraZeneca (AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial evaluating two . . . → Read More: Company Update (NASDAQ:AMGN): Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis